RALLYBIO CORPORATION Capital Expenditures
RALLYBIO CORPORATION (RLYB) reported Capital Expenditures of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2025-03-13
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2023-12-31 was $12.00K.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for fiscal 2023 was $12.00K, a 77.78% decline from fiscal 2022.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for fiscal 2022 was $54.00K, a 83.78% decline from fiscal 2021.
- RALLYBIO CORPORATION payments to acquire property, plant, and equipment for fiscal 2021 was $333.00K, a 143.07% increase from fiscal 2020.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 | |||
| 2023-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.00K derived: sum of 2 quarters · filed 2025-03-13 | $12.00K derived: sum of 3 quarters · filed 2025-03-13 | $12.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $4.00K derived: sum of 4 quarters · filed 2024-03-12 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $4.00K derived: sum of 3 quarters · filed 2024-03-12 | $18.00K derived: sum of 4 quarters · filed 2024-03-12 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $4.00K derived: sum of 2 quarters · filed 2024-03-12 | $18.00K derived: sum of 3 quarters · filed 2024-03-12 | $54.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $18.00K derived: sum of 2 quarters · filed 2023-11-09 | $54.00K 10-Q · filed 2023-11-09 | $191.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $50.00K 10-Q · filed 2023-08-08 | $187.00K derived: sum of 3 quarters · filed 2023-08-08 | $317.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $36.00K 10-Q · filed 2023-05-09 | $173.00K derived: sum of 2 quarters · filed 2023-05-09 | $303.00K derived: sum of 3 quarters · filed 2023-05-09 | $307.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $267.00K derived: sum of 2 quarters · filed 2023-03-06 | $271.00K derived: sum of 3 quarters · filed 2023-03-06 | $333.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $134.00K derived: sum of 2 quarters · filed 2022-11-07 | $196.00K 10-Q · filed 2022-11-07 | $302.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $66.00K 10-Q · filed 2022-08-08 | $172.00K derived: sum of 3 quarters · filed 2022-08-08 | $195.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $62.00K 10-Q · filed 2022-05-10 | $168.00K derived: sum of 2 quarters · filed 2022-05-10 | $191.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $129.00K derived: sum of 2 quarters · filed 2022-03-15 | $137.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $31.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $8.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |